Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network

肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络

基本信息

  • 批准号:
    10700170
  • 负责人:
  • 金额:
    $ 62.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-23 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract: Cirrhosis and its complications including hepatocellular carcinoma (HCC) are increasingly common causes of morbidity and mortality in the United States. The central hypotheses of this application are that (1) the creation of a prospective cohort study of patients with compensated cirrhosis will facilitate the generation of novel prediction models based on the clinical, behavioral, metabolic, and biomarker data we collect to predict clinical decompensation, (2) this cohort can validate and then be supplemented by a larger electronic health record (EHR)-based virtual cohort, the latter of which will enable validation of electronic cirrhosis phenotypes and subsequent analysis of real-world data on the safety and effectiveness of individual lipid-lowering agents on multiple outcomes among patients with cirrhosis and (3) long-term statin therapy will provide clinical benefits in preventing hepatic decompensation and HCC independent of its lipid lowering effect. To investigate these hypotheses, we propose unique approaches to both the cohort study and statin-based clinical trial for the Liver Cirrhosis Network (LCN). In Aim 1a, we will create a prospective cohort of highly phenotyped patients with compensated NASH, ALD, cholestatic and cryptogenic cirrhosis, in order to facilitate the interrogation of biospecimens, patient reported behaviors and outcomes, and clinical data for novel predictors of disease progression, and to understand through serum lipoproteins measurement the complex interaction between cirrhosis and lipid metabolism. In Aim 1b, we will create a large LCN-wide EHR-based virtual cohort of patients with compensated cirrhosis, prospectively validate electronic phenotypes for cirrhosis and its clinical complications with our in-person cohort, and evaluate the use, safety and effectiveness of different classes of lipid lowering medications upon outcomes in this large real-world virtual cohort. In Aim 2, we propose to study the safety and efficacy of statins in preventing clinical decompensation among patients with NAFLD or ALD cirrhosis while exploring the potential pleiotropic mechanisms of statins. In this trial, patients with and without an established non-hepatic indication for lipid lowering will be randomized to pravastatin v. alirocumab (stratum 1) or placebo (stratum 2), respectively. This innovative approach to the statin-based clinical trial will acknowledge the patient's baseline indication for lipid-lowering therapy, and offer an alternative lipid lowering pathway in PCSK9 inhibition, which has similar or greater LDL-lowering potency but lacks the pleotropic effects of statins, to allow for novel insights into mechanisms by which statins might impact outcomes independent of its effects on lipids. Throughout the cohort and interventional trials, we will study lipoprotein metabolism, inflammatory markers, and collect microbiome and biospecimens for future translational research to better understand the mechanisms behind disease progression in cirrhosis and for any potential impact of pravastatin and alirocumab on clinical outcomes. These innovative strategies therefore leverage both cohort and clinical trial designs to maximize the knowledge gained and improve clinical outcomes among patients with cirrhosis.
项目总结/文摘:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT S BROWN其他文献

ROBERT S BROWN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT S BROWN', 18)}}的其他基金

Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络
  • 批准号:
    10492742
  • 财政年份:
    2021
  • 资助金额:
    $ 62.28万
  • 项目类别:
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络
  • 批准号:
    10311423
  • 财政年份:
    2021
  • 资助金额:
    $ 62.28万
  • 项目类别:
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network
肝硬化结果预防的策略和治疗:STOP-C 肝硬化网络
  • 批准号:
    10690121
  • 财政年份:
    2021
  • 资助金额:
    $ 62.28万
  • 项目类别:
Race & Viral Resistance in Chronic Hepatitis C (VIRAHEP*
种族
  • 批准号:
    6407013
  • 财政年份:
    2001
  • 资助金额:
    $ 62.28万
  • 项目类别:
Race & Viral Resistance in Chronic Hepatitis C (VIRAHEP*
种族
  • 批准号:
    6765821
  • 财政年份:
    2001
  • 资助金额:
    $ 62.28万
  • 项目类别:
PEB IFN AND RIBAVIRIN VERSUS REBETRON IN HEPATITIS C
PEB IFN 和利巴韦林与 ReBETRON 治疗丙型肝炎的对比
  • 批准号:
    6567820
  • 财政年份:
    2001
  • 资助金额:
    $ 62.28万
  • 项目类别:
Race & Viral Resistance in Chronic Hepatitis C (VIRAHEP*
种族
  • 批准号:
    6896117
  • 财政年份:
    2001
  • 资助金额:
    $ 62.28万
  • 项目类别:
Race & Viral Resistance in Chronic Hepatitis C (VIRAHEP*
种族
  • 批准号:
    6647205
  • 财政年份:
    2001
  • 资助金额:
    $ 62.28万
  • 项目类别:
ADEFOVIR DIPIVOXIL FOR PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION
阿德福韦酯用于慢性乙型肝炎病毒感染患者
  • 批准号:
    6567828
  • 财政年份:
    2001
  • 资助金额:
    $ 62.28万
  • 项目类别:
Race & Viral Resistance in Chronic Hepatitis C (VIRAHEP*
种族
  • 批准号:
    6517968
  • 财政年份:
    2001
  • 资助金额:
    $ 62.28万
  • 项目类别:

相似国自然基金

greenwashing behavior in China:Basedon an integrated view of reconfiguration of environmental authority and decoupling logic
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    万元
  • 项目类别:
    外国学者研究基金项目

相似海外基金

Systematization of Cognitive Behavioral Therapy based on the influence of rule-governed behavior in frequent stealing behavior
基于规则行为对频繁偷盗行为的影响的认知行为治疗的系统化
  • 批准号:
    23K18975
  • 财政年份:
    2023
  • 资助金额:
    $ 62.28万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Organizational Behavior Management in Various Welfare Facilities Starting with Behavioral Records
各类福利机构的组织行为管理从行为记录入手
  • 批准号:
    23K17566
  • 财政年份:
    2023
  • 资助金额:
    $ 62.28万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
An Empirical Study on a Behavioral Model for Invoking the Potential Demand of Micro-Tourism through the Provision of Behavior Change Triggers
通过提供行为改变触发因素激发微旅游潜在需求的行为模型实证研究
  • 批准号:
    23K11632
  • 财政年份:
    2023
  • 资助金额:
    $ 62.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of behavior modification approach using cognitive behavioral therapy for patients with higher brain dysfunction
使用认知行为疗法开发针对重度脑功能障碍患者的行为矫正方法
  • 批准号:
    23K02986
  • 财政年份:
    2023
  • 资助金额:
    $ 62.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Combined Dialectical Behavior Therapy and Digital Cognitive Behavioral Therapy for Insomnia for Adolescents at High Risk for Suicide: A Pilot RCT
辩证行为疗法和数字认知行为疗法相结合治疗自杀高危青少年的失眠:一项试点随机对照试验
  • 批准号:
    10643478
  • 财政年份:
    2023
  • 资助金额:
    $ 62.28万
  • 项目类别:
The Effects of Scholarship on Student's Learning Behavior Focusing on PreferenceDevelopments and Expansions of Behavioral Economics Approach
奖学金对学生学习行为的影响关注偏好行为经济学方法的发展和扩展
  • 批准号:
    22K13722
  • 财政年份:
    2022
  • 资助金额:
    $ 62.28万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Multisensory integration at the cell, circuit, and behavioral levels: How audiovisual signals drive dynamic courtship behavior in Drosophila melanogaster
细胞、回路和行为层面的多感觉整合:视听信号如何驱动果蝇的动态求偶行为
  • 批准号:
    10389197
  • 财政年份:
    2022
  • 资助金额:
    $ 62.28万
  • 项目类别:
Multisensory integration at the cell, circuit, and behavioral levels: How audiovisual signals drive dynamic courtship behavior in Drosophila melanogaster
细胞、回路和行为层面的多感觉整合:视听信号如何驱动果蝇的动态求偶行为
  • 批准号:
    10828249
  • 财政年份:
    2022
  • 资助金额:
    $ 62.28万
  • 项目类别:
Quantifying Behavioral Factors Related to Sedentary Behavior of Disabled Elderly
量化与残疾老年人久坐行为相关的行为因素
  • 批准号:
    22K21213
  • 财政年份:
    2022
  • 资助金额:
    $ 62.28万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Construction of tsunami evacuation behavior database containing geographic characteristics and behavioral contexts and utilization of it for promoting residents' behavior to prepare for evacuation
构建包含地理特征和行为背景的海啸疏散行为数据库,并利用它来促进居民做好疏散准备的行为
  • 批准号:
    22K04641
  • 财政年份:
    2022
  • 资助金额:
    $ 62.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了